Roche has received CE Mark for its Accu-Chek Solo micropump system. The company will start a pilot commercialisation phase for this new insulin delivery system in Austria, Poland, Switzerland and the UK in the coming weeks and is currently conducting a clinical study in several European countries.
Roland Diggelmann, CEO Roche Diagnostics says of the pump, “This important milestone will enable us to further expand access to insulin pump therapy to those people with diabetes who can benefit most from this therapy option – so they can spend more time in their ideal target range and experience an improved quality of life. The new modular design of our Accu-Chek Solo micropump system responds to the needs of people with diabetes to give them more discretion and flexibility.”
According to press information, “The Accu-Chek Solo micropump system allows for convenience and personalisation in insulin pump therapy while contributing to a more targeted and effective diabetes management. It offers the functionalities of a traditional insulin pump alongside with the technological advancement of tube-free insulin delivery. The system consists of two parts: a small, lightweight and semi-disposable insulin micropump and a remote control incorporating blood glucose monitoring and bolus advice. The system provides bolus insulin dosing, both from the remote control, or directly from the pump. In addition, the system connects to Roche Diabetes Care’s digital solutions such as the Accu-Chek Smart Pix system, a proven tool for efficient, effective and personalised diabetes management.”
There will be an update when news about the launch of the product in the UK becomes available.
News items and features like this appear in the Desang Diabetes Magazine, our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it’s free, and you can easily unsubscribe should you wish to).